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[57] ABSTRACT 
Certain novel aryl sulfonyl fluorides, their preparation, 
and their use in inhibiting serine proteases with chymo-
trypsin-like and elastase-like specificity. 
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ARYL SULFONYL FLUORIDE COMPOUNDS 
BACKGROUND OF THE INVENTION 
Selective and reactive protease inhibitors are widely 5 
used in biomedical research. They are used to identify 
the nature of new proteolytic enzymes encountered in 
isolation and characterization studies. They are also 
used both in research and industrially to prevent unde-
sired proteolysis of proteins and peptides during the 10 
production, isolation, purification, transport and stor-
age of these valuable materials. They could also be used 
industrially to increase the yields of proteins and pep-
tides produced by cloning or fermentation by inhibiting 
proteolysis of the products due to proteases released by 15 
the parent organism or by contaminating organisms in 
the growth medium. Protease inhibitors could also be 
used to protect proteins and peptides during storage or 
use from proteolysis which would destroy or alter the 
activity and/or function of the peptides or proteins. 20 
changes in the inhibitor (cf. Biochim. Biophys. Acta 
525, pp 171-179(1978)). While a difference in rate of 
26,000 fold was observed between the fastest and slow-
est inhibitor, the absolute reactivities of the inhibitors 
were comparatively slow. It is an object of this inven-
tion to find a novel group of aryl sulfonyl fluorides 
which will rapidly and selectively inhibit elastase-like 
and chymotrypsin-like enzymes. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Certain aryl sulfonyl fluorides have been found to 
selectively inhibit elastase by blocking the active site of 
the enzyme by sulfonylation of the enzyme's active site 
serine residue. The inhibition reaction occurs very rap-
idly. The novel aryl sulfonyl fluoride elastase inhibitors 
have the following structural formula: 
Such uses would include their addition to antibodies, wherein 
enzymes, plasma proteins or other proteins which are X is selected from the group consisting of NH, 0, S, 
widely sold for use in clinical analysis, biomedical re- CH2, and CF2 (but not larger groups such as 
search, therapy, and for many other reasons. NCH3, nor groups such as NS02CF3 which have 
Serine proteases are the most widely distributed class 25 more than 2 atoms other than hydrogen or fluo-
of proteolytic enzymes. Serine proteases can be further rines). 
divided into three main classes based on their substrate Y is selected from the group consisting of CO, S, SO, 
specificity: chymotrypsin-like, elastase-like, and tryp- O, CF2, NH, and CH2 (but not larger groups such 
sin-like. In addition, there are a few other serine pro- as so2 or -C(OCH3)= which contain 3 or more 
teases which do not fit into any of the above three 30 atoms other than hydrogen or a halide). 
groups. This invention relates only to chymotrypsin- RI is a c 1_5 fluoroalkyl (such as CF3, CF2CF3, or 
like and elastase-like enzymes. Chymotrypsin and CF2CF2CF3, but not longer or more bulky groups 
chymotrypsin-like enzymes normally cleave peptide such as cF3CO-Ala, CF3(CF2)6, 
bonds in proteins and peptides where the amino acid cF3CONH(CH2)5, or C6Fs). 
residue on the carbonyl side of the split bond (Pt resi- 35 The Rt group must be a perfluoroalkyl and not an 
due) is typically Trp, Tyr, Phe, Met, Leu or other alkyl group, and could be branched. Substitution of a 
amino acid residues which contain aromatic or large few of the fluorine atoms in the perfluoroalkyl group 
alkyl side chains. Elastase and. elastase-like enzymes, on for hydrogens or other halides will not significantly 
the other hand, cleave peptide bonds where the Pt alt th •t f th lfi 1 fl ·d t inhib.t 
amino acid residue is much smaller, typically Ala, Val, 40 er e capaci Y 0 e su ony. uon e o i 
Ser, Leu and other similar amino acids. All of the above elastase. One or two of the carbons m the perfluoroalkyl 
enzymes have extensive secondary specificity and rec- group could be r~pla.ce~ by 0, S, NH, or CH2 as long as 
ognize amino acid residues removed from the Pt resi- t~e RI group mamtains i~s.fluorocarbon and hydropho-
due. Chymotrypsin-like and elastase-like enzymes are bic character .. W~en R is _a ?4:-s perfluoroalkyl, t~e 
widely distributed. They are found in leukocytes (white 45 s~fonyl fluonde is also an inhibitor of chymotrypsm-
blood cells), mast cells, pancreatic juice, and many like enzyme~. . . 
other cell types and fluids in higher organisms. They are The substituents on the aromatic rmg must b~ ort;ho 
also secreted by many types of bacteria, yeast, viruses to each other and not meta or P'.1fa .. The aromatic rm~ 
and parasites. These enzymes can be very destructive if c?uld .be replace.ct ~y heter?cychc rmgs such as a pyn-
not proper1y controlled. Thus there is a need for selec- 50 dine rmg or a t~adiazole rmg. The -C~- could be 
tive and reactive inhibitors for these enzymes. replaced by a cts double bond or substituted double 
Sulfonyl fluorides have been widely used as inhibitors bond such as -CH=CH-, -CMe=CH-, -C-
of serine proteases since their intial discovery by Fahr- Me=CMe- (Me=methyl), or -CCFJ=CCF3-. 
ney and Gold (cf. J. Am. Chem. Soc. 85, pp. 997-1000 The following novel compounds are representative 
(1963)). These reagents, which are fairly stable in aque- 55 of the invention: 
ous solution, inhibit serine proteases by sulfonylation of 
the active site serine residue to give a stable sulfonyl 
enzyme derivative. Sulfonyl fluorides have been shown 
to inhibit most serine proteases including chymotrypsin 
(cf. Baker and Hurlbut, J. Med. Chem., 12, pp 118-122 60 
(1969)), trypsin, elastase, and complement, coagulation, 
and fibrinolytic serine proteases. However, sulfonyl 
fluorides are not usually considered to be highly spe-
cific and in fact phenylmethanesulfonyl fluoride is usu- Another novel aryl sulfonyl fluoride elastase inhibitor 
ally considered to be a fairly general inhibitor of serine 65 of this invention has the following structural formula: 
proteases. Lively and Powers showed that the specific-
ity of sulfonyl fluorides toward elastase, cathepsin G 
and chymotrypsin could be improved with structural 
3 4 
complete and faster inhibition will be obtained if an 
inhibitor concentration of 10 to 1000 fold higher than 
the protease(s) concentration is used. The time required 
for complete inhibition will be dependent on the con-
wherein R2 is a linear group of 0.9 to 2.0 run bridging 
the two aromatic rings. The R2 group is composed of 6 
to 13 small uncharged atomic groupings such as NH, 
CO, CH2, S02, 0, NH, S and CF2. Ideal inhibitors are 
formed when R2 has 8 or 11 atomic groupings. Suitable 
R2 groups are 
-CH2-0-CO-NH-(CH2)2-CO-NH- and 
s centration of inhibitor used, but can be calculated from 
the measured rates of inhibition (cf. Yosimura, Barker, 
and Powers, J. Biol. Chem., 257, pp 5077-5084 (1982)). 
-CH2-0-CO-NH-(CH2)s-CO-NH-. 
10 
The following examples are given to illustrate the 
invention and are not intended to limit it in any manner. 
EXAMPLE 1 
Preparation of 2-(CF3CF2CONH)-C61i4-S02F 
Pentafluoropropionic anhydride (2 ml) was added to 
1 g of 2-NH2-C6li4-S02F. The mixture was stirred 
The substituents on the aromatic ring must be meta to 
each other and not ortho or para. Both aromatic rings 
could contain substituents such as F, OMe, or N02. 
Both aromatic rings could be replaced by heterocyclic 
rings such as pyridine or thiadiazole rings. 
The following novel compounds are representative 
of the invention: 
3-C6ff5CH20CONH(CH2)2CONH-C6-
J4-S02F 
15 for 10 min after completion of the exothermic reaction 
and then poured into ice water. The precipitate was 
filtered and recrystallized from methanol-water yield-
ing 0.93 g of a white solid with mp 70 deg centigrade. 
Anal. Calcd. for C9HsF6N03S: C, 33.66; H, 1.57; N, 
20 4.36; S, 9.98. Found: C, 33.72, H, 1.62; N, 4.46; S, 9.94. 
3-C6ff5CH20CONH(CH2)5CONH-C6-
l4-S02F 
Certain aryl sulfonyl fluorides have been found to 
selectively inhibit chymotrypsin-like enzymes such as 25 
bovine chymotryp!!in, human cathepsin G, human skin 
chymase, rat mast cell chymase I and rat mast cell chy-
mase IL The novel aryl sulfonyl fluorides of this inven-
tion have the following structural formula: 
EXAMPLE2 
Preparation of 
2-(C6HsCH20-CO-NHCH2CONH)-Crr 
l4-S02F 
To a stirred solution of 1.6 g of 2-NH2-Crr 
l4-S02F in 40 ml of pyridine cooled to -20 deg 
centigrade was added dropwise 0.40 ml of PCh. The 
solution was stirred for 45 min at - 20 and then warmed 
wherein R3 is a linear spacing group of 0.45 to 1.7 run 
bridging the two aromatic rings. The R3 group is com-
posed of 3 to 11 small uncharged atomic groupings such 
30 to room temperature. C6HsCH20CONHCH2C02H (1.9 g) was added and the reaction refluxed for 3 hrs. 
The product was purified on a silica gel column by 
elution with 3% ethyl acetate-benzene. The oily prod-
uct was triturated with ether yielding 0. 745 g of a white 
as NH, CO, CH2, CF2, S02, 0, NH, and S. Suitable 35 
spacing groups are -CH20CONH(CH2)11CONH-
with n= l, 2, or 5. If n=2 or 5 the inhibitor is very 
selective toward human skin chymase. Another suitable 
spacing group is CONHCH2CONH. Another suitable 
spacing grouping is -CH2NHCONH- and the inhibi- 40 
tor is very selective toward mast cell chymase. 
The substituents on the second aromatic ring must be 
ortho to each other and not meta or para. Both aromatic 
rings could contain substituents such as F, OMe, or 
N02. Both aromatic rings could be replaced by hetero- 45 
cyclic rings such as pyridine or thiadiazole. 
The following novel compounds are representative 
of the invention: 
2-C@i5CH20-CO-NH(CH2)CONH-C6-
l4-S02F 
2-C6HsCH20-CO-NH(CH2)2-CONH-C6-
l4-S02F 
2-C@i5CH20-CO-NH(CH2)5-CONH-C6-
l4-S02F 
2-C6ff5CONHCH2CONH-C614-S02F 
2-C6ff5CH2NHCONH-C614-S02F 
50 
55 
To use the above identified inhibitors, they are dis- 60 
solved in an organic solvent such as dimethylsulfoxide 
or ethanol and are added to an aqueous solution con-
taining the protease which is to be inhibited such that 
the final concentration of organic solvent is 25% or less. 
The inhibitors may also be added as solids or in suspen- 65 
sion. The final concentration of the inhibitor in the 
inhibition solution should be at least equal to that of the 
protease or proteases in the solution. However, more 
solid with mp 110-112. Anal. Calcd. for 
C16H1sFN205S: C, 52.46;, H, 4.098; N, 7.65. Found: C, 
52.72; H, 4.14; N, 7.59. 
Other illustrative examples are incorporated by refer-
ence herein in the Yoshimura, Barker and Powers publi-
cation (cf. J. Biol. Chem. 257, pp 5077-5084(1982)). The 
applicant was the director of the research coauthored 
by others. 
What is claimed is: 
1. A compound of the formula: 
wherein 
X is selected from the group consisting of NH, 0, S, 
and CF2, 
Y is selected from the group consisting of CO, S, SO, 
0, CF2, NH, and CH2, and 
R 1 is a C1.5 perfluoroalkyl. 
2. A substituted diphenyl compound of the formula: 
3-(C6ffs-R2)-C614-S02F 
wherein R 2 is linear group of 0. 9 to 2.0 run bridging the 
two phenyl rings and is composed of 6 to 13 uncharged 
atomic groupings selected from the group consisting of 
CO, CH2, 0, NH, S, and CF2. 
3. A substituted diphenyl compound of the formula: 
2-(C6ffs-R 3)-C614-S02F 
wherein R3 is a linear spacing gorup of 0.45 to 1.7 run 
bridging the two phepyl rings and is composed of 3 to 
11 uncharged atomic groupings selected from the group 
consisting of CO, CH2, CF2, S02, 0, NH, and S. 
• • • • • 
